Shares of Crinetics Pharmaceuticals Inc. (CRNX), a clinical-stage pharmaceutical company developing novel therapeutics for endocrine diseases and endocrine-related tumors, have lost over 40% from their 52-week high of $62.53, recorded last November, and trade around $35.
The company's lead drug candidate is Paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 agonist in development for the proposed treatment of people with acromegaly.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.